Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| bioAffinity Technologies Inc | BIAF | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2.79 | 06:05:55 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 2.79 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 0.9548 - 3.62 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 2.79 | USD |
bioAffinity Technologies Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 26.51M | 9.50M | - | 5k | -8.15M | -0.86 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
bioAffinity Technologies News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIAF Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 2.48 | 3.10 | 2.31 | 2.74 | 217,417 | 0.31 | 12.50% |
| 1 Month | 2.06 | 3.10 | 1.9601 | 2.53 | 177,626 | 0.73 | 35.44% |
| 3 Months | 1.60 | 3.62 | 1.39 | 2.31 | 229,174 | 1.19 | 74.38% |
| 6 Months | 1.34 | 3.62 | 1.15 | 2.25 | 114,304 | 1.45 | 108.21% |
| 1 Year | 1.96 | 3.62 | 0.9548 | 2.20 | 63,665 | 0.83 | 42.35% |
| 3 Years | 8.40 | 15.55 | 0.9548 | 3.87 | 630,187 | -5.61 | -66.79% |
| 5 Years | 8.40 | 15.55 | 0.9548 | 3.87 | 630,187 | -5.61 | -66.79% |
bioAffinity Technologies Description
| bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company is involved in developing technologies that, in the future, will be able to detect and monitor diseases of the lung and other cancers and treat many cancers. |
